ERITROPOYETINA HUMANA RECOMBINANTE PDF
Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.
|Published (Last):||9 July 2012|
|PDF File Size:||20.35 Mb|
|ePub File Size:||15.17 Mb|
|Price:||Free* [*Free Regsitration Required]|
Despite long clinical experience with ESAs, the mechanisms involved in their elimination have not been fully eeritropoyetina. Similar inter-individual differences were found in time needed to reach Epo C max. Nonerythropoietin receptor-mediated pathways may play a major role. However, the influence of ESA pharmacokinetics on hematopoietic response has not been sufficiently investigated.
Eritropoyetina Humana Recombinante –
Eur J Haematol ; The values of C max and t max are comparable to those found by other authors, taking into account the above mentioned differences in methodology.
Renal Injury from Drugs and Chemicals, third edition. We recently showed that BEN hemodialysis patients required a higher dose of recombinant human erythropoietin for maintaining the target hemoglobin level than patients with other kidney diseases.
Balkan endemic nephropathy, Human recombinant erythropoietin, Pharmacokinetics.
Eritropoyetina Humana Recombinante Delta –
Erythropoietin resistance and survival in non-dialysis patients with stage chronic kidney disease and heart disease. However, for protein and peptide drugs, dependency on active tissue uptake, binding to intra- and extravascular proteins can substantially increase the value of Vd.
Res Commun Mol Pathol Pharmacol ; It seems most likely that both native Epo and recombinant drugs recombinanet degraded following receptor-mediated uptake, eritropoyetima in the bone marrow. The dose of beta-Epo was adjusted to attain the hemoglobin target range defined by European best practice guidelines for the management of anemia in patients with chronic renal failure Also, the difference in other pharmacokinetic parameters presented in Table 3 remained insignificant after adjustment.
When adjusted these differences remained statistically significant 0.
recombinqnte This work was conducted as a part of projects No and funded by the Ministry of Science, Education and Technological Development, Belgrade, Republic of Serbia. Renal function, protein excretion and pathology of Balkan endemic nephropathy. Erythropoietin Epo concentration was determined in all samples on the same day by chemiluminescent immunoassay for erythropoietin on an Immulite analyzer Siemens Healthcare Diagnostics.
Statistical analysis The results were expressed as mean values with standard deviations. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers.
Eritropoyetina Humana Recombinante Delta
The Ethics Committee of the Clinical Center of Serbia evaluated and approved the study and the participants gave informed consent. European best practice guidelines working group: Although basal plasma Epo concentration was similar in BEN Always humanna your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. We comply with the HONcode standard for trustworthy health information – verify here.
A total of 24 subjects was selected from the population of hemodialysis patients according to the following inclusion criteria: This means it is still under development and may contain inaccuracies.
Eritropoyetina Humana Recombinante
Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients. The results were expressed as mean values with standard deviations.
Introduction Anemia was described as a characteristic of Balkan endemic nephropathy BEN in early reports on the disease, 1,2 so Danilovic 3 included it among the criteria for diagnosis.
Subscribe to free Drugs.
The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. After beta-Epo administration plasma Epo slowly increased and C max was achieved after Kidney Int Suppl ; Analysis of covariance ANCOVA was used to adjust these differences for patient characteristics that differed between groups: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.
Serum levels of iron, ferritin, transferrin saturation, C-reactive protein CRPalbumin, urea, creatinine, calcium, phosphorus and parathyroid hormone PTH were determined in each patient at the time of study. J Clin Pharmacol ; Results The study involved 24 hemodialysis patients, 10 patients with BEN and 14 with other kidney diseases, selected from 96 patients 40 BEN and 56 others who met the inclusion criteria.
To view content sources and attributions, please refer to our editorial policy. A number of pharmacokinetic studies of ESA have been published, but comparison between them is difficult due to numerous methodological differences.
Related Posts (10)
- TEORIA DEL DESARROLLO PSICOSOCIAL DE ERIK ERIKSON EBOOK DOWNLOAD
- UN GRITO DESESPERADO LIBRO COMPLETO EPUB DOWNLOAD
- EL ARTE DE HACER DINERO MARIO BORGHINO EBOOK
- LEY 906 DE 2004 ACTUALIZADA EBOOK
- TRIANGULOS DEL CUELLO ANATOMIA PDF
- EJERCICIOS CON GOMAS ELASTICAS EBOOK
- ESFEROCITOSIS HEREDITARIA PDF
- MOHINI THEEVU TAMIL NOVEL PDF
- PINZAMIENTO SUBACROMIAL PDF
- UN BUEN BISTEC JACK LONDON PDF